FDA wants classwide boxed warning on all commercial CAR-T therapies amid secondary cancer safety probe
As many have feared, the FDA’s investigation into secondary T-cell cancers following treatment with existing CAR-T therapies is poised to lead to a classwide black box warning. For all six commercial CAR-T therapies, the FDA is requiring label updates to include T-cell malignancies in the boxed…
#fda #bristolmyerssquibb #gileadsciences #johnsonjohnson #bristol #breyanzi #yescarta #tecartus #legendbiotech #carvykti